BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-211@pharmaconomics
DTSTAMP:20260707T034447Z
DTSTART;VALUE=DATE:20260221
DTEND;VALUE=DATE:20260222
SUMMARY:VNDA PDUFA — Bysanti
DESCRIPTION:The FDA's approval decision on Bysanti for bipolar I disorder and schizophrenia is due Feb 21\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1347178/000162828026007256/vnda8-k2112026exhibit991.htm\n\nTrack it: https://www.pharmaconomics.com/e/211
URL:https://www.pharmaconomics.com/e/211
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:VNDA catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR